Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07780968 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA

Study acronym: ZOLA
StatusNot Yet Recruiting
PhaseNot specified
Started2026-10-01
View on ClinicalTrials.gov ↗

Amendment history

2026-08-21
Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility v1
Eligibility criteria-30 characters
[...] HC2+ with ISH positivity) locally advanced or metastatic GEA (HER2+ la/m GEA) Documented plan to initiate a zanidatamab-containing therapy as first line (1L) treatment Sufficient cognitive capacity and language profic [...]
Secondary endpointsdetails revised at 1 of 18 entries
2026-08-19
Original filing
The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line (1L) zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with unresectable, locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA) (HER2+ la/m GEA).
Trial Details
NCT Number NCT07780968
Lead Sponsor Jazz Pharmaceuticals
Conditions Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer, Stomach Cancer
Enrollment 300 participants
Start Date 2026-10-01
Primary Completion 2031-10-01 (estimated)
Study Completion 2031-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-25